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Publisher Correction: Preclinical amyloid
pathology biomarker positivity: effects on
tau pathology and neurodegeneration
K. Höglund1,2, S. Kern1,3, A. Zettergren1,3, A. Börjesson-Hansson1,3, H. Zetterberg1,4, I. Skoog1,3 and K. Blennow1
Correction to: Translational Psychiatry; https://doi.org/
10.1038/tp.2016.252; published online 10 January 2017.
The Article was originally published under a CC BY-
NC-ND 4.0 license, but has now been made available
under a CC BY 4.0 license. The PDF and HTML versions
of the Article have been modiﬁed accordingly.
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